An inordinate (well, about 200,000) number of shares crossed on June 28 at 3.40ish. Interesting activity over the last week to take the price down to $3 before this deal was crossed.
I've been waiting for a change in substantial holder statement to come out.
Nothing yet, but it will be interesting to see.
As you all know we shall get to see the CEO present the company to institutional investors and analysts on July 10.
We should all keep a little eye on Viropharma: watch for their announcements, any shift in strategy. I note they are presenting at the same meeting as BOTA but then they present at many such meetings. See what they have to say. BOTA has a lot of cash, just sitting there, no debt and a nice grant for 3 more years. VPHM are down to 90 million free cash (ex repayment of notes), have stopped their share buyback, and might be looking for an acquisition. Antiflu is not really the kind of disease they now concentrate on, but they have looked at anti-rhinovirus with pleconaril in the past. And they are now on the Board.
No comments:
Post a Comment